Breaking News
September 19, 2018 - FDA-approved ‘safe’ daily BPA exposure may contribute to insulin resistance
September 19, 2018 - Research finds physical connection between the brain’s fluid reservoirs and meningeal lymphatics
September 19, 2018 - Biomedical review finds failure rates in some surgical mesh treatments to be unacceptably high
September 19, 2018 - Researchers develop more accurate measure of body fat
September 19, 2018 - Doctors and students rally to support gun violence research, education
September 19, 2018 - LEO Pharma and MorphoSys announce expansion of strategic alliance to develop peptide-derived drugs
September 19, 2018 - Seniors in pain hop aboard the canna-bus
September 19, 2018 - New compound could prevent malaria parasites from maturing inside mosquito
September 19, 2018 - Scientists find alterations in blood flow in response to body position change
September 19, 2018 - UNC Health Care extends free access to virtual care service in the aftermath of Hurricane Florence
September 19, 2018 - Opioid Refills Rare After Rhinoplasty
September 19, 2018 - Corn, obesity, and navigating healthy eating choices as a parent
September 19, 2018 - Journal editor aims to prompt thoughtful review of ethics in precision health
September 19, 2018 - Researchers identify key step in how plant cells respond to pathogens
September 18, 2018 - Researchers analyze how exposure to silver nanoparticles affects zebrafish
September 18, 2018 - Study shows air pollution may be bad for the fetus
September 18, 2018 - Coffee May Have Another Perk for Kidney Patients
September 18, 2018 - Tongue-in-cheek Nobels honor nutritional analysis of cannibalism, roller-coaster kidney stones treatment
September 18, 2018 - Progress, priorities, challenges are focus of State of Stanford Medicine | News Center
September 18, 2018 - Established Alzheimer’s Risk Gene Has a New Role
September 18, 2018 - Hospitalization after antibiotic initiation found to be higher for people with Alzheimer’s disease
September 18, 2018 - Many children with special healthcare needs do not have access to ‘PCMH-concordant’ care
September 18, 2018 - Investigational nasal influenza vaccine tested in children and teens
September 18, 2018 - Lymphatic vessels surrounding the brain play crucial role in multiple sclerosis, research suggests
September 18, 2018 - New fiber laser-based ultrasound sensor may have potential applications in medical diagnostics
September 18, 2018 - Protect your heart and health during ‘dog days’ of summer
September 18, 2018 - Faculty receive awards for promise in biomedical research, clinical care | News Center
September 18, 2018 - Digital games for CVD-related self-management improve exercise capacity and energy expenditure
September 18, 2018 - Aluminum inclusions help enhance adsorption of chemo drugs onto active carbon delivery capsule
September 18, 2018 - Adding PET scans to CT imaging can change treatment for women with cervical cancer
September 18, 2018 - UCSF awarded $20 million grant to study impacts of new, emerging tobacco products
September 18, 2018 - Human brains may be wired to prefer lying on the couch, suggests research
September 18, 2018 - Zika virus vaccine shows promise for treatment of fatal glioblastoma
September 18, 2018 - Theravance Biopharma and Mylan to Report New Data from Phase 3 Studies of Yupelri (revefenacin) in Oral Presentation at European Respiratory Society International Congress 2018
September 18, 2018 - INSiGHT identifies unique retinal regulatory genes
September 18, 2018 - Diversity, science leadership grants awarded to student-faculty pairs | News Center
September 18, 2018 - Many parents blame electronics for sleep problems among teens
September 18, 2018 - Researchers study neuronal activity in brain that prevents individuals from doing physical activity
September 18, 2018 - Purifying Proteins from Mammalian Cell Culture
September 18, 2018 - Researchers map 3D structure of toxic proteins used by Pseudomonas aeruginosa to trigger infection
September 18, 2018 - Outcome of ACL reconstruction related to the way you move post-surgery
September 18, 2018 - Study aims to investigate risk factors for PPCs in surgical patients with gastric cancer
September 18, 2018 - Ardelyx Submits New Drug Application for Tenapanor for IBS-C
September 18, 2018 - Sociodemographic disparities in eyeglass use among elderly
September 18, 2018 - New Drug Shows Promise for Progressive Form of MS
September 18, 2018 - Babies exposed to higher levels of organochlorine compounds in womb may have worse lung function
September 18, 2018 - Women exposed to trauma in their lives gave birth to underweight male infants
September 18, 2018 - Probiotic supplementation may reduce use of antibiotics, scientific analysis shows
September 18, 2018 - Resveratrol decreases pain severity and levels of inflammatory biomarkers in osteoarthritis patients
September 18, 2018 - Research shows pollution is reaching the placenta
September 18, 2018 - KAIST researchers develop heart-targeting drug delivery technology using tannin acid
September 18, 2018 - Muscle relaxants used during general anesthesia can increase risk of pulmonary complications
September 18, 2018 - Silicone breast implants may increase risk of rare adverse outcomes in women
September 18, 2018 - Pediatricians Have a Role in Encouraging Play Among Children
September 18, 2018 - California’s Medicaid program hits ‘print’ when the feds need info
September 18, 2018 - Genes, environment and schizophrenia—new study finds the placenta is the missing link
September 18, 2018 - Boehringer Ingelheim announces study results of COPD patients treated with Spiolto Respimat
September 18, 2018 - PAREXEL launches Patient Innovation Center to improve drug development process
September 18, 2018 - Children’s National and NIAID launch pediatric clinical research partnership
September 18, 2018 - Researchers may be overlooking complexities in social relations of primates
September 18, 2018 - Key signaling molecule that helps stem cells make healthy bone declines as we age
September 18, 2018 - More women veterans with chronic pain use CIH therapies than men
September 18, 2018 - As Earth Warms, Heat-Related Deaths Will Multiply
September 18, 2018 - Labetalol use up for patients with preeclampsia and asthma
September 18, 2018 - MoreGrasp project shows significant results in field of thought-controlled grasp neuroprosthetics
September 18, 2018 - Drumming can benefit school children with autism
September 18, 2018 - Busyness can help people to make virtuous choices, research shows
September 18, 2018 - Two-minute bursts of in-class exercise breaks do not disrupt learning and teaching
September 18, 2018 - New online tools aid surgeons and specialists who care for older people
September 18, 2018 - Researchers use CRISPR to identify gene that helps cells resist flavivirus infection
September 18, 2018 - Brain’s support cells may play a central role in repetitive behaviors related to OCD
September 18, 2018 - Scientists discover novel mechanism by which synthesized proteins reach target compartment in cell
September 18, 2018 - Easy and rapid test for viral infections can cut antibiotic use, hospitalizations
September 18, 2018 - Gunshot victims more likely to require blood transfusions and die than other trauma patients
September 18, 2018 - Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer
September 18, 2018 - Older adults fitted with cochlear implants exhibit poor brain function
September 18, 2018 - Inexpensive testing spurs cancer patients’ relatives to assess own disease risk | News Center
September 18, 2018 - Aging may have originated at the very beginning of life, says study
September 18, 2018 - New research on sperm quality updates advice for couples trying to conceive
September 18, 2018 - Paracetamol use in infancy may increase risk of developing asthma by the age of 18
Patients with Moderate-to-Severe Ulcerative Colitis Achieved Clinical and Endoscopic Remission with Mirikizumab in Phase 2 Trial

Patients with Moderate-to-Severe Ulcerative Colitis Achieved Clinical and Endoscopic Remission with Mirikizumab in Phase 2 Trial

image_pdfDownload PDFimage_print

INDIANAPOLIS, June 5, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today new safety and efficacy data from a Phase 2 study evaluating mirikizumab in patients with moderate-to-severe ulcerative colitis (UC). The results showed that patients treated with mirikizumab achieved significantly greater rates of clinical remission at 12 weeks compared to placebo. Detailed results from the Phase 2 trial will be presented today in a late-breaking abstract session at Digestive Disease Week (DDW) in Washington, D.C.

“We are proud to present these Phase 2 results for mirikizumab at DDW, which represent the first public disclosure of data on the safety and efficacy of an IL-23p19 monoclonal antibody in patients with moderate-to-severe UC,” said Lotus Mallbris, M.D., vice president, immunology platform team leader, Lilly Bio-Medicines. “These positive data affirm our confidence in the potential for mirikizumab to be an option for people living with immune-mediated diseases looking for a treatment that addresses their life-altering symptoms. We look forward to advancing our Phase 3 clinical development program for mirikizumab in UC, in addition to continuing our ongoing Phase 3 trial for mirikizumab in moderate-to-severe plaque psoriasis.”

The Phase 2 study evaluated the safety and efficacy of mirikizumab compared to placebo in patients with moderate-to-severe UC who had previously failed conventional or biologic therapy. In the study, patients were randomized to receive either mirikizumab (50 mg or 200 mg with the possibility of exposure-based increases up to 600 mg, or 600 mg fixed dose) or placebo. The primary and secondary endpoints at 12 weeks were the percentages of patients treated with mirikizumab achieving clinical remission, clinical response, endoscopic healing, endoscopic remission and symptomatic remission.

At 12 weeks, patients achieved the following response rates:

  • Clinical remission: Across all doses studied, between 11.5 percent to 22.6 percent of patients treated with mirikizumab achieved clinical remission, compared to 4.8 percent of those treated with placebo (nominal p-value
  • Clinical response: Across all doses studied, between 41.3 percent to 59.7 percent of patients treated with mirikizumab achieved clinical response, compared to 20.6 percent of those treated with placebo (nominal p-value
  • Endoscopic healing: Across all doses studied, between 13.1 percent to 30.6 percent of patients treated with mirikizumab achieved endoscopic healing, compared to 6.3 percent of those treated with placebo (nominal p-value

Additionally, greater proportions of patients treated with mirikizumab achieved endoscopic remission and symptomatic remission compared to placebo at 12 weeks. The proportion of patients achieving endoscopic remission was not statistically significant.

The incidence of serious adverse events and treatment-emergent adverse events (TEAEs) was similar across treatment groups. Among the most common TEAEs reported across all treatment groups, rates of nasopharyngitis, anemia and headache were similar between mirikizumab and placebo groups; a greater proportion of patients reported worsening of ulcerative colitis in the placebo group compared to patients in the mirikizumab groups.

“I am particularly encouraged by the symptomatic response and remission data we’ve seen thus far, and look forward to having data from later periods in the study to provide insight about the degree to which endoscopy results continue to improve over time, as we’ve observed in other clinical programs for UC,” said William J. Sandborn, M.D., Chief, Division of Gastroenterology, Professor of Medicine at the University of California San Diego School of Medicine. “Data from this Phase 2 trial indicate that if approved, mirikizumab may be an effective treatment option for patients with moderate-to-severe UC.”

About Mirikizumab

Mirikizumab is a humanized IgG4 monoclonal antibody that binds to the p19 subunit of interleukin 23. Mirikizumab is being studied for the treatment of immune diseases, including psoriasis, ulcerative colitis and Crohn’s disease.

About Ulcerative Colitis

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that affects the colon.1 UC occurs when the immune system sends white blood cells into the lining of the intestines, where they produce chronic inflammation and ulcerations.1 UC affects millions of patients globally.2 Early and sustained symptom relief, improvement in the appearance of the mucosa, and clinical remission are important treatment goals for healthcare providers and patients.2 There is an unmet need for treatment options for UC that provide meaningful symptom relief and deliver sustained clinical remission.

About the Mirikizumab Phase 2 Trial in UC

The Phase 2, multi-center, randomized, double-blind, placebo-controlled trial was designed to evaluate the safety and efficacy of mirikizumab in patients with moderate-to-severe UC. The primary endpoint in the study was the percentage of patients achieving clinical remission at 12 weeks, as defined by a Mayo rectal bleeding subscore of 0; a stool frequency subscore of 0 or 1, plus a decrease ≥1 from baseline; and an endoscopy subscore of 0 or 1. The study also evaluated secondary endpoints, including clinical response, as defined by a Mayo subscore decrease of ≥2 points and a ≥35 percent change in from induction baseline, excluding PGA; endoscopic healing, as defined by a Mayo endoscopy subscore of 0 or 1; endoscopic remission, as defined by a Mayo endoscopy subscore of 0; and symptomatic remission, as defined by a stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0. For additional information on this trial, please visit clinicaltrials.gov.

About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and www.lilly.com/newsroom/social-channels.

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about mirikizumab as a potential treatment for patients with ulcerative colitis, psoriasis and Crohn’s disease, and reflects Lilly’s current belief. As with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that future study results will be consistent with the results to date, that mirikizumab will receive regulatory approvals, or be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly’s most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

1 What is Ulcerative Colitis? Crohn’s and Colitis Foundation Website. http://www.crohnscolitisfoundation.org/what-are-crohns-and-colitis/what-is-ulcerative-colitis/. Accessed June 5, 2018.
2 Adelphi Data 2017.

SOURCE Eli Lilly and Company

Posted: June 2018

About author

Related Articles